keyword
MENU ▼
Read by QxMD icon Read
search

Olmesartan

keyword
https://www.readbyqxmd.com/read/29748863/repaglinide-irbesartan-drug-interaction-effects-of-slco1b1-polymorphism-on-repaglinide-pharmacokinetics-and-pharmacodynamics-in-chinese-population
#1
Qi Pei, Jun-Yan Liu, Ji-Ye Yin, Guo-Ping Yang, Shi-Kun Liu, Yi Zheng, Pan Xie, Cheng-Xian Guo, Mi Luo, Hong-Hao Zhou, Xi Li, Zhao-Qian Liu
PURPOSE: On account of the potential inhibition of OATP1B1 (organic anion transporting polypeptide) by angiotensin II receptor blockers (ARBs) and the effects of SLCO1B1 (solute carrier organic anion transporter family member) polymorphism, the aim of current study is to assess the impact of ARBs on the pharmacokinetics (PK) and pharmacodynamics (PD) of repaglinide in Chinese healthy volunteers with different SLCO1B1 genotypes. METHODS: The in vitro study was conducted on irbesartan, valsartan, olmesartan, and losartan by using HEK293 cells transfected with OATP1B1...
May 11, 2018: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29732226/acute-gastrointestinal-bleeding-in-olmesartan-associated-collagenous-gastroduodenitis-a-potential-endoscopic-complication
#2
Rachel Hudacko, Lance Siegel
Collagenous gastroenteritis is a rare disease that is known to be associated with the drug olmesartan, an angiotensin II receptor antagonist used to treat hypertension. It is characterized histologically by increased subepithelial collagen deposition with associated inflammation and epithelial injury. Endoscopically, the mucosa appears inflamed and friable and may be nodular or atrophic. We report a case of acute gastric bleeding on direct mucosal contact during endoscopy in a patient with olmesartan-associated collagenous gastroduodenitis to raise awareness of this potential endoscopic complication...
2018: Case Reports in Gastrointestinal Medicine
https://www.readbyqxmd.com/read/29700766/fabrication-of-nanosuspension-directly-loaded-fast-dissolving-films-for-enhanced-oral-bioavailability-of-olmesartan-medoxomil-in-vitro-characterization-and-pharmacokinetic-evaluation-in-healthy-human-volunteers
#3
Jihad Mahmoud Alsofany, Manal Yassin Hamza, Aly Ahmed Abdelbary
Olmesartan medoxomil (OM) is an antihypertensive drug with poor water solubility and low oral bioavailability (28.6%). Accordingly, this study aimed to formulate and evaluate OM nanosuspension incorporated into oral fast-dissolving films (FDFs) for bioavailability enhancement. OM nanosuspension was prepared by antisolvent-precipitation-ultrasonication method and characterized regarding particle size (122.67 ± 5.03 nm), span value (1.40 ± 0.51), and zeta potential (- 46.56 ± 1.20 mV). Transmission electron microscopy (TEM) of the nanosuspension showed spherical non-aggregating nanoparticles...
April 26, 2018: AAPS PharmSciTech
https://www.readbyqxmd.com/read/29694249/olmesartan-combined-with-renal-denervation-reduces-blood-pressure-in-association-with-sympatho-inhibitory-and-aldosterone-reducing-effects-in-hypertensive-mice-with-chronic-kidney-disease
#4
Masaaki Nishihara, Ko Takesue, Yoshitaka Hirooka
BACKGROUND: Augmented sympathetic nerve activity (SNA) and renin-angiotensin-aldosterone system (RAAS) activity are involved in the pathogenesis of hypertension (HT) accompanied by chronic kidney disease (CKD). Oxidative stress in the hypothalamus increases SNA in HT. Administration of an angiotensin ΙΙ receptor blocker (olmesartan; OLM) or renal denervation (RDN) exerts an antihypertensive effect in HT with CKD; however, the precise mechanisms of the combination therapy are not fully elucidated...
April 25, 2018: Clinical and Experimental Hypertension: CHE
https://www.readbyqxmd.com/read/29683146/effects-of-olmesartan-and-azilsartan-on-albuminuria-and-the-intrarenal-renin-angiotensin-system
#5
Takeshi Takami, Sadanori Okada, Yoshihiko Saito, Yoko Nishijima, Hiroyuki Kobori, Akira Nishiyama
Purpose: Olmesartan and azilsartan decrease blood pressure more effectively than other angiotensin receptor blockers (ARBs). ARBs additionally decrease the urinary albumin to creatinine ratio (UACR), a urinary albumin marker, and urinary angiotensinogen (u-AGT), an intrarenal renin-angiotensin system activity marker. We examined the effects of these ARBs on blood pressure, UACR, and u-AGT in patients with uncontrolled hypertension. Methods: Patients with uncontrolled hypertension treated with conventional ARBs, excluding olmesartan and azilsartan, for over 8 weeks were enrolled...
January 2018: World journal of research and review
https://www.readbyqxmd.com/read/29648464/home-blood-pressure-and-cardiovascular-outcomes-in-very-elderly-patients-receiving-antihypertensive-drug-therapy-a-subgroup-analysis-of-home-blood-pressure-measurement-with-olmesartan-naive-patients-to-establish-standard-target-blood-pressure-honest-study
#6
Ikuo Saito, Kazuomi Kario, Toshio Kushiro, Satoshi Teramukai, Mai Yaginuma, Natsuko Zenimura, Yoshihiro Mori, Yasuyuki Okuda, Kazuyuki Shimada
The appropriate target blood pressure (BP) in elderly patients with hypertension remains uncertain. We investigated the relationship between morning home systolic blood pressure (MHSBP) during follow-up and cardiovascular (CV) risk in outpatients receiving olmesartan-based treatment aged <75 years (n = 16799) and ≥75 years (n = 4792) in the HONEST study. In the follow-up period (mean 2.02 years), the risk for major CV events was significantly higher in patients with MHSBP ≥155 mmHg compared with <125 mmHg in both age groups in Cox proportional hazards model adjusted for other risk factors and there was no significant difference in trend between the two groups (interaction P = 0...
March 28, 2018: Clinical and Experimental Hypertension: CHE
https://www.readbyqxmd.com/read/29643115/chronic-at1-blockade-improves-glucose-homeostasis-in-obese-oletf-rats
#7
Ruben Rodriguez, Jacqueline N Minas, Jose Pablo Vazquez-Medina, Daisuke Nakano, David G Parkes, A Nishiyama, Rudy M Ortiz
Obesity is associated with the inappropriate activation of the renin-angiotensin-system (RAS), which increases arterial pressure, impairs insulin secretion, and decreases peripheral tissue insulin sensitivity. RAS blockade reverses these detriments; however, it is not clear whether the disease state of the organism and treatment duration determine the beneficial effects of RAS inhibition on insulin secretion and insulin sensitivity. Therefore, the objective of this study was to compare the benefits of acute vs...
April 11, 2018: Journal of Endocrinology
https://www.readbyqxmd.com/read/29628463/-vascular-smooth-muscle-cell-response-to-cyclic-mechanical-stretch-and-aortic-dissection
#8
Masanori Yoshizumi, Jing Zhao, Yoji Kyotani
Acute aortic dissection is the most common life-threatening vascular disease, with sudden onset of severe pain and a high fatality rate. The pulsatile nature of blood flow exposes vascular smooth muscle cells (VSMCs) in the vessel wall to cyclic mechanical stretch (CMS), which evokes VSMC death, phenotypic switching, and migration, leading to aortic dissection. We have revealed that CMS of rat aortic smooth muscle cells (RASMCs) caused JNK- and p38-dependent cell death and that a calcium channel blocker, azelnidipine and an angiotensin II receptor antagonist, olmesartan decreased the phosphorylation of JNK and p38 and, subsequently, decreased cell death by CMS...
2018: Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
https://www.readbyqxmd.com/read/29609611/association-between-industry-payments-and-prescribing-costly-medications-an-observational-study-using-open-payments-and-medicare-part-d-data
#9
Manvi Sharma, Aisha Vadhariya, Michael L Johnson, Zachary A Marcum, Holly M Holmes
BACKGROUND: While many new medications may offer advantages over existing drugs, some newer drugs are reformulations of existing products that provide little innovation or incremental benefit while driving up drug costs. Despite the lack of benefit of these medications, prescribers may be motivated by payments made by the pharmaceutical industry. The objective of the study was to determine the association between payments made to physicians by the pharmaceutical industry and prescriptions for certain selected costly brand name drugs...
April 2, 2018: BMC Health Services Research
https://www.readbyqxmd.com/read/29601411/antihypertensive-drug-use-in-resistant-and-nonresistant-hypertension-and-in-controlled-and-uncontrolled-resistant-hypertension
#10
Alejandro de la Sierra, Pedro Armario, Anna Oliveras, José R Banegas, Manuel Gorostidi, Ernest Vinyoles, Juan J de la Cruz, Julián Segura, Luis M Ruilope
BACKGROUND AND AIM: Treatment-resistant hypertension (TRH) is associated with particular clinical features, nonadherence, and suboptimal treatment. We assessed possible associations of antihypertensive drug classes, specific agents inside each class, and types of combinations, with the presence of non-TRH vs. TRH, and with controlled vs. uncontrolled TRH. METHODS: Comparisons were done in 14 264 patients treated with three drugs (non-TRH: 2988; TRH: 11 276) and in 6974 treated with at least four drugs (controlled TRH: 1383; uncontrolled TRH: 5591)...
March 29, 2018: Journal of Hypertension
https://www.readbyqxmd.com/read/29571021/linalyl-acetate-prevents-olmesartan-induced-intestinal-hypermotility-mediated-by-interference-of-the-sympathetic-inhibitory-pathway-in-hypertensive-rat
#11
Soonho Kwon, Yu Shan Hsieh, You Kyoung Shin, Purum Kang, Geun Hee Seol
Olmesartan-associated enteropathy (OAE) is a life-threatening pathological condition, but its underlying mechanisms have not been elucidated. Although intestinal hypermotility is frequently accompanied by chronic diarrhea, there have been no studies of olmesartan-induced hypermotility. Intestinal motility should be well regulated by the enteric nervous system, but degeneration of enteric neurons has been reported in patients with chronic diarrheal diseases, such as irritable bowel syndrome, suggesting a connection between OAE and intestinal hypermotility...
March 20, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29560673/an-unusual-cause-of-severe-persistent-diarrhoea
#12
Bram Verstockt, Barbara Deleenheer, Filip Sermon, Kris Van Der Steen, Jo Vandervoort
We present two cases of patients with severe persistent diarrhoea, in whom duodenal biopsies revealed villous atrophy that could be attributed to the use of olmesartan. The differential diagnosis of villous atrophy without serological markers of celiac disease should include drugs as possible cause, with olmesartan as a recently discovered culprit. Gastroenterologist should be aware of this entity.
July 2017: Acta Gastro-enterologica Belgica
https://www.readbyqxmd.com/read/29527375/long-term-consequences-of-fetal-angiotensin-ii-receptor-antagonist-exposure
#13
K Wegleiter, M Waltner-Romen, R Trawoeger, U Kiechl-Kohlendorfer, E Griesmaier
Fetal angiotensin II receptor antagonist exposure is associated with major complications and even death when administered during pregnancy. Neonates frequently require intensive care treatment, and mortality is high. Despite this well-known risk potential, a considerable number of women still receive angiotensin II receptor antagonists during pregnancy to treat arterial hypertension. Although clinical symptoms in the neonatal period are well described, few reports address long-term follow-up after fetal exposure to angiotensin II receptor antagonists...
2018: Case Reports in Pediatrics
https://www.readbyqxmd.com/read/29513178/an-unusual-cause-of-severe-persistent-diarrhoea
#14
B Verstockt, B Deleenheer, F Sermon, K Van Der Steen, J Vandervoort
We present two cases of patients with severe persistent diarrhoea, in whom duodenal biopsies revealed villous atrophy that could be attributed to the use of olmesartan. The differential diagnosis of villous atrophy without serological markers of celiac disease should include drugs as possible cause, with olmesartan as a recently discovered culprit. Gastroenterologist should be aware of this entity.
July 2017: Acta Gastro-enterologica Belgica
https://www.readbyqxmd.com/read/29504252/long-term-efficacy-and-tolerability-of-azilsartan-medoxomil-chlorthalidone-vs-olmesartan-medoxomil-hydrochlorothiazide-in-chronic-kidney-disease
#15
George L Bakris, Lin Zhao, Stuart Kupfer, Attila Juhasz, Michie Hisada, Eric Lloyd, Suzanne Oparil
An open-label, long-term study evaluated safety and tolerability of azilsartan medoxomil/chlorthalidone (AZL-M/CLD) vs olmesartan/hydrochlorothiazide (OLM/HCTZ) in hypertensive participants with stage 3 chronic kidney disease. Initial therapy was AZL-M/CLD 20/12.5 mg (n = 77) or OLM/HCTZ 20/12.5 mg (n = 76), but could be up-titrated (AZL-M/CLD to 40/25 mg; OLM/HCTZ to 40/25 mg [US] or 20/25 mg [Europe]) with other agents added during weeks 4-52. Primary endpoint was proportion of participants with ≥ 1 adverse event (AE) through week 52...
April 2018: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/29504233/treatment-of-hypertension-in-ckd-patients-with-azilsartan-chlorthalidone-vs-olmesartan-hydrochlorothiazide
#16
Walter M van der Merwe
No abstract text is available yet for this article.
April 2018: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/29462508/comparative-effectiveness-of-an-angiotensin-receptor-blocker-olmesartan-medoxomil-in-older-hypertensive-patients
#17
Josep Redon, Michael A Weber, Paul-Egbert Reimitz, Ji-Guang Wang
The efficacy and safety of olmesartan medoxomil (OM) vs active control (AC) monotherapy among elderly patients aged 60-79 years (N = 4487) was evaluated by meta-analysis (25 studies). In all patients, change from baseline to end point in blood pressure (BP) was significantly greater with OM vs AC (-19.5/-11.9 vs -16.8/-10.7 mm Hg). Greater proportions of OM- vs AC-treated patients achieved BP goals. In patients with impaired renal function (estimated glomerular filtration rate <60 mL/min/1.73 m2 ), OM treatment resulted in a greater mean change from baseline in systolic BP vs AC (-21...
February 2018: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/29457309/severe-intestinal-malabsorption-associated-with-ace-inhibitor-or-angiotensin-receptor-blocker-treatment-an-observational-cohort-study-in-germany-and-italy
#18
Peter Malfertheiner, Claudio Ripellino, Nazarena Cataldo
PURPOSE: The angiotensin II receptor blocker (ARB) olmesartan has been recently associated with sprue-like enteropathy (SLE), a gastrointestinal condition characterized by intestinal malabsorption (IM) and severe diarrhea. Whether the increased risk of SLE is substance-specific or a class effect involving all ARBs is uncertain. The aim of this study is to assess the risk of enteropathy associated with ARBs and angiotensin converting enzyme inhibitors (ACE-i) by using data from large administrative and claim databases...
February 19, 2018: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/29453084/solid-lipid-nanoparticles-as-an-efficient-drug-delivery-system-of-olmesartan-medoxomil-for-the-treatment-of-hypertension
#19
Nilima T Pandya, Parva Jani, Jigar Vanza, Hemal Tandel
The aim of the current investigation was to develop solid lipid nanoparticles of olmesartan medoxomil using hot homogenization method to improve its oral bioavailability. Central composite design was applied to optimize the formulation variables; lipid X1 (Glyceryl monostearate) and surfactant X2 (Poloxamer: Tween 80). The particle sizes were in the nanometer range and spherical shaped for all prepared solid lipid nanoparticles formulations and the zeta potential absolute values were high, predicting good long-term stability...
May 1, 2018: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/29417244/secondary-raynaud-s-phenomenon-and-skin-necrosis-of-toes-in-the-paraplegic-patient-with-hypertension
#20
Yong Jig Lee, Kisoo Park
We present two cases of paraplegic patients who developed secondary Raynaud's phenomenon. A 43-year-old man with paraplegia presented with dark purple discoloration and skin defects on his left second and third toes and complained of a cold sensation in both feet for a period of 1 year. He had been taking diuretics for 4 years. The capillary refilling time for both affected toes was delayed. His antihypertensive drug was changed to a calcium channel blocker under suspicion of Raynaud's phenomenon aggravated by hydrochlorothiazide, and the capillary refilling time normalized within 3 days...
February 7, 2018: Drug Safety—Case Reports
keyword
keyword
11664
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"